For example, Mounjaro is approved to treat Type 2 diabetes, but it also reduces appetite
(PubMed) Lavery AM, Brender JD, Zhao H, et al
How Endogenous Hormone Release Differs from Synthetic GLP-1 Drugs The study centers on a difference between endogenous GLP-1 stimulation, the bodys own secretion of glucagon-like peptide-1 from intestinal cells, and prescription receptor agonists
The most common adverse effects include nausea, vomiting, diarrhea, constipation, decreased appetite, and abdominal discomfort
GLP-1 (glucagon-like peptide-1) suppresses appetite and slows digestion, so you feel full longer after eating